tirzepatide surpass SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Tirzepatide versus insulin glargine in
Pay in 4 interest-free payments of $5.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
02188-7/asset/1f15c5ee-e9c1-4058-8e74-d7dafaec62ef/main.assets/gr2.jpg)


























